SCHEMBL2770529

SCHEMBL2770529

CCCCCCC(=O)C(=O)NCCCC(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G4A P47712 1/20 1.00
PLA2G2A P14555 3/20 0.93
GPR84 Q9NQS5 7/20 0.61
PPARG P37231 7/20 0.61
PPARD Q03181 7/20 0.61
PPARA Q07869 7/20 0.61
HDAC11 Q96DB2 5/20 0.61
TSHR P16473 4/20 0.61
PTPN1 P18031 3/20 0.61
ALDH1A1 P00352 2/20 0.61
TLR2 O60603 2/20 0.61
TDP1 Q9NUW8 2/20 0.61
FABP4 P15090 2/20 0.61
SLC22A6 Q4U2R8 1/20 0.61
SLC22A8 Q8TCC7 1/20 0.61
MEN1 O00255 1/20 0.61
ESR1 P03372 1/20 0.61
ALOX15 P16050 1/20 0.61
PDE4A P27815 1/20 0.61
KMT2A Q03164 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1877382 1.00 PLA2G4A (1.00) PLA2G4APLA2G2AGPR84PPARGPPARD
SCHEMBL28776220 0.96 PLA2G2A (1.00) PLA2G4APLA2G2AGPR84PPARGPPARD
SCHEMBL4795104 0.91 PLA2G4A (0.82) PLA2G4APLA2G2APPARGPPARDPPARA
SCHEMBL4927236 0.91 PLA2G4A (0.82) PLA2G4APLA2G2APPARGPPARDPPARA
SCHEMBL12636328 0.89 PLA2G2A (0.79) PLA2G4APLA2G2AEPHX2
SCHEMBL29449856 0.84 PLA2G4A (0.73) PLA2G4APLA2G2AKMT2AEPHX2
SCHEMBL7155979 0.81 EPHX2 (0.76) PLA2G4AGPR84PPARGPPARDPPARA
SCHEMBL12836993 0.81 EPHX2 (0.76) PLA2G4AGPR84PPARGPPARDPPARA
SCHEMBL2769524 0.81 EPHX2 (0.76) PLA2G4AGPR84PPARGPPARDPPARA
SCHEMBL15297165 0.81 EPHX2 (0.76) PLA2G4AGPR84PPARGPPARDPPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7745489-B2 Compositions and methods for inhibition of phospholipase A2 mediated inflammation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-06-29 US claimed
EP-1490328-A4 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION UNIV CALIFORNIA (US) 2007-08-15 EP claimed
US-20050148549-A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-07-07 US claimed
EP-1490328-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION The Regents of The University of California (US) 2004-12-29 EP claimed
WO-2003076389-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-09-18 WO claimed
US-7745489-B2 Compositions and methods for inhibition of phospholipase A2 mediated inflammation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-06-29 US disclosed
EP-1490328-A4 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION UNIV CALIFORNIA (US) 2007-08-15 EP disclosed
US-20050148549-A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2005-07-07 US disclosed
EP-1490328-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION The Regents of The University of California (US) 2004-12-29 EP disclosed
WO-2003076389-A1 COMPOSITIONS AND METHODS FOR INHIBITION OF PHOSPHOLIPASE A2 MEDIATED INFLAMMATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2003-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148549-A1 Compositions and methods for inhibition of phospholipase a2 mediated inflammation PLA2G4A, PLA2G4B, PLA2G1B PLA2G4A 1/4885PLA2G2A 5/4885GPR84 1047/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.